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Chemokines (Chemo-attractant Cytokines), acting through
their signaling receptors, along with adhesion molecules such
as integrins and selectins, selectively co-ordinate the move-
ment of immune cells into and out of specific tissue micro-
environments, being an essential component for their
recruitment to the infection sites and, consequently, for the
arising of the immune response [1].
The large family of chemokines is divided into four
subfamilies based on the position of the cysteine residues at their
amino terminus: the CC chemokines (CCL1-28) with no ami-
noacidic residues between the first two cysteines, the CXC
chemokines (CXCL1-16) with a single non-conserved amino-
acid and the only one CX3C chemokine (CX3CL1) with three
aminoacid between them. Finally, the C chemokines are devoid
of the two cysteines characterizing the other chemokines [1].
Furthermore, chemokines can be further divided, according
to their expression, into inducible, or inflammatory, and
constitutive, or homeostatic: the former are produced in
response to different inflammatory stimuli such as infections or
tissue damage while the latter are normally expressed, driving
leukocyte homing within lymphoid organs. The biological* Corresponding author. Tel: þ39 091 6555916; fax: þ39 091 6555901.
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proliferation, apoptosis, cytokine release, degranulation and
Th1/Th2 polarisation, are carried out through the interaction and
activation of a distinct subfamily of 18 mammalian structurally
related G-protein-coupled signaling receptors, divided into four
groups based on the chemokine subclass specificity [1]. Besides
the conventional receptors, there exists a small family of atyp-
ical and promiscuous receptors sharing a structural similarity
with them but referred as ‘‘silent chemokine receptors’’ [2] for
their apparent inability to signal upon ligand binding [3].
The lack of signaling functions seems to be due to the
altered DRYLAIV motif in the second intracellular loop
which, in signaling chemokine receptors, is responsible for
G-protein coupling to the receptors; all non conventional
receptors are characterized by its absence [4]. Recently, Nibbs
and Graham’s [3] showed that introducing the DRY motif back
into the second intracellular loop restores the signaling func-
tion to D6, a decoy receptor for pro-inflammatory chemokines,
confirming that this alteration is definitely responsible for the
lack of the signaling functions in silent receptors.
2. Non conventional chemokine receptors
Three silent chemokine receptors have been identified to
date in mammals: DARC (Duffy Antigen Receptor for
Chemokines), CCX-CKR and D6 receptors.
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site of leukocyte extravasation, where it binds mostly CC and
CXC pro-inflammatory chemokines [1], and on erythrocytes
where it is useful for the entry of some malarial parasites [5].
CCX-CKR binds the constitutive CC chemokines, CCLs
19, 21, 25 and weakly, in humans, the follicular CXC che-
mokine, CXCL13 and probably does not mediate chemotaxis
and leukocyte recruitment, being not involved in inflammation
[6].
At present, the D6 receptor is the focus of intense investi-
gation in the field of inflammation since it binds many
inflammatory CC chemokines (CCLs 2, 3L1, 4, 5, 7, 8, 11e14,
22 and weakly CCL17), without triggering any signals in
target cells [7].
Interestingly, many reports identify for D6 a role as
a functional decoy receptor that traffics to and from the cell
surface to internalize its ligand [8] through recycling endo-
somes. Once internalized, chemokines are targeted for
degradation while the D6 receptor returns to be exposed on the
cell surface. The molecular mechanisms of this recycling are
still unclear even if it is believed that the D6 receptor is subject
to a constitutive ligand-independent phosphorylation [9],
helping mediate ligand-independent exocytosis, and that
b-arrestins are not necessary for D6 internalizzation.
Conversely, other reports suggest that D6 is not phosphory-
lated and its constitutive internalization is b-arrestins-depen-
dent [10].
The D6 receptor is mainly expressed on endothelial cells
lining lymphatic channels draining tissues such as skin, gut
and syncitiotrophoblast layer of placenta, where it removes
inflammatory chemokines, promoting the protection of the
immune/inflammatory privilege of the fetus [11].
Furthermore, D6 expression in hematopoietic stem cells
(HSC), megakaryocytes, mast cells and DC was supported by
the presence of multiple GATA1-binding sites on the D6
promoter. Graham and colleagues [12] have demonstrated that
GATA1 is a physiological regulator of D6 expression using
a model of mice with a conditional deletion in GATA1,
associated to a transcriptional switch-off of D6 expression, in
their dendritic cells (DCs).
Interestingly, conversely to data reported in the literature
detecting an anti-inflammatory role for D6 owing to its
capacity to scavenge circulating pro-inflammatory CC che-
mokines, studies in Experimental Autoimmune Encephalo-
myelitis (EAE), a mouse model of multiple sclerosis, have
suggested that D6 functions may be variable and dependent on
the setting of the inflammatory conditions. In these EAE
model, D6-deficient mice display a significantly lower
immune response with a reduced inflammatory leukocyte
infiltration in the spinal chord and, consequently, a decreased
demyelination [13]. This favourable outcome of the pathology
in D6-null mice seems to be associated to a significantly
attenuated immune response to the EAE-inducing ‘mog’
antigen, although the reasons are still unclear.
In contrast, confirming the anti-inflammatory role of D6, its
overexpression in human breast cancer cells seems to inhibit
proliferation in vitro, tumorigenesis, lung and lymp nodemetastasis in vivo [14], and to induce a reduction of circulating
chemokines, such as CCL2 and CCL5, of vessel density, and
tumor-associated macrophage infiltration. Furthermore, D6
expression seems to be positively correlated to disease-free
survival rate in cancer patients.
3. Non conventional cytokine receptors
Besides chemokines decoy receptors, there exist several
cytokine receptors able to generate the interferencemechanisms
required for a tight regulation of the immune responses [15],
such as Toll/IL-1R 8 (Tir8), also known as single Ig IL-1-related
receptor (SIGIRR). Tir8 is a member of the IL-1 receptor/Toll-
like receptor (TLR) superfamily and an intracellular decoy for
components of the signaling pathway. It has a small single
extracellular Ig domain, an intracellular TIR domain and
a cytosolic tail formed by 95 amino acids [16].
Tir8 has been reported to act as a potent inhibitor of the NF-
kB activation by members of the IL-1/TLR family, because its
intracellular domain lacks two essential amino acids (Ser447
and Tyr536) in its highly conserved TIR domain, and a trap-
ping agent for TNFR-associated Factor 6 (TRAF6) and IL-1R-
associated kinase 1 (IRAK1) [16]. Thus, Tir8 sequesters the
TLR signaling complexes, tuning the action of inflammatory
cytokines/chemokines by inhibiting IL-1R and TLR4
signaling [17]. For this reason, Tir8 is referred as the member
of the TLR/IL-1R superfamily with unique anti-inflammatory
properties.
The Tir8 molecule is expressed on epithelial cell surface
and DCs. It has been reported [18] that Tir8-deficient mice
show an increased susceptibility to the systemic toxicity of
bacterial lipopolysaccharide (LPS) and to dextran sulphate
sodium (DSS)-induced intestinal inflammation, proving its
crucial role in damping inflammation in the gastrointestinal
tract.
More recently, Tir8 has also been reported to negatively
regulate in vivo the inflammatory response in infection
[18,19].
The role of TLRs in the inflammatory conditions associated
to the fungal infection is still unclear. Although inflammation
is regarded as crucial in the adaptive immune response
towards fungi, its dysregulation may be more harmful for the
host than fungal infection itself [20]. Some data provide
evidence that Tir8 is required for the host resistance to fungal
infection by down-regulating IL-1 signaling-dependent acti-
vation of Th17 cell responses, as recently demonstrated for the
infection with Candida albicans [21].
Tir8 is known to suppress antimicrobial immunity [20,21]
but some recent data identify autoimmunity control as a novel
function of this receptor [22]. Tir8 might contribute to the
control of autoimmunity suppressing TLR signaling in DCs
and autoreactive B cells [23], which are in vitro activated by
immune complexes containing the lupus autoantigens
U1snRNP or nucleosomes via TLR7 and TLR9, respectively
[24,25].
In vivo studies with TLR7 antagonists [26] Tlr7-deficient
mice [27] or TLR7 overexpression confirm this concept for
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Tlr9-deficient mice are still a matter of debate [29].
Concluding, given their ability to bind pro-inflammatory
chemokines and cytokines with no signaling function, the role
proposed for ‘‘decoy receptor’’ is to limit the negative and
harmful effects of the inflammation caused by the immune
responses evoked by self antigens in the autoimmune diseases,
by tumors or microorganisms, such as Mycobacterium
Tuberculosis (M. tuberculosis), the etiological agent of
tuberculosis.
4. The tight correlation between chemokines, cytokines
and granuloma formation in tuberculosis
The formation of granulomas at the site of mycobacterial
infection is an essential component of host immunity for
controlling infection. This process is dependent on the acti-
vation of mycobacteria-reactive T lymphocytes [30], particu-
larly IFNg-secreting CD4 and CD8 T cells [31]. Granuloma
formation, however, is a complex process that requires not
only the activation of lymphocytes, but also their recruitment
with monocytes to the site of the infection, migration into the
tissues, and juxtaposition around mycobacteria-infected
macrophages [30]. This colocalization facilitates the activation
of bactericidal mechanisms in infected macrophages by T cell-
derived cytokines [30]. Some mycobacteria, however, survive
within macrophages, and persistent antigenic stimulation
perpetuates the process, leading to chronic granuloma
formation characterized by dense accumulations of infected
macrophages, epithelioid cells, and T lymphocytes [30]. These
granulomas contain the mycobacterial infection and prevent
dissemination to other organs, but they are also responsible for
lung immunopathology, as the granulomas displace and
destroy parenchymal tissue [32]. One of the major roles of the
granuloma is to localize and contain not only the bacteria but
also the inflammatory response to the bacteria itself. Indeed, if
immune cells are not tightly controlled within the lungs, this
could lead to excess inflammation. Thus, rigorous control of
the organization of granulomas is likely necessary to prevent
immunopathology. In most cases, after the repair of an
inflamed or damaged tissue, inflammation subsides and the
tissue returns to its homeostatic norm [33]. However, if the
resolution phase of inflammation is ineffective, chronic
inflammatory pathologies may develop [33]. Failure to resolve
ongoing inflammation is an invariable key feature of pathol-
ogies, which are typically characterized by the high-level
expression of inflammatory cytokines and chemokines [34].
TNFa and the related cytokine lymphotoxin [35] are potent
pro-inflammatory cytokines with a wide range of activities in
both the inflammatory and immune responses, and they play
an essential role in host resistance against infection with
M. tuberculosis and other mycobacteria [36]. TNFa-deficient
mice infected by aerosol with M. tuberculosis develop normal
T cell responses to mycobacterial antigens, but because of the
failure of granuloma formation in the infected organs they are
profoundly susceptible to the infection, succumbing with
extensive necrosis in the lungs and infected organs [36]. Otherthan TNFa, the role of other soluble mediators in regulating
granuloma formation and persistence is poorly understood.
Concluding, cytokines, chemokines and their receptors are
surely involved in cell migration and are logical candidates
for a role in granuloma formation, although their expression
has been studied to a limited degree in M. tuberculosis
infection [37].
5. Chemokines and tuberculosis
A better understanding of the immunological mechanisms
of pathogenesis and protection is of essential importance for
the design of novel vaccines and immunotherapies against
tuberculosis. It has been proposed that the protective response
to M. tuberculosis infection requires CD4 and CD8 lympho-
cytes, the Th1-type cytokines IFNg and TNFa, and activated
macrophages [38]. The cooperation between the cells and
cytokines requires close interaction, which is achieved after
migration and granuloma formation in the lungs. The granu-
loma formation is the hallmark of infection in the lung
containing the mycobacteria and creating a microenvironment
for immune cell interaction, limiting M. tuberculosis growth
and dissemination. Chemokines are potent leukocyte
activators and chemoattractants aiding granuloma formation
and thought to be critical for the immune response to
M. tuberculosis [37]. In vitro experiments demonstrated that
M. tuberculosis infection of bone marrow-derived mouse
macrophages results in the expression of TNFa, as well as
several chemokines, including ligands for the chemokine
receptors CXCR3, CCR5, and CCR2. Neutralization of TNFa
by using antibody or TNFR1-deficient macrophages demon-
strated that expression of certain chemokines (CXCL9/mon-
okine induced by IFNg, CXCL10/IFN-inducible protein 10,
CXCL11/IFN-inducible T cell chemoattractant, CCL5/
RANTES, and CCL2/MCP-1) after M. tuberculosis infection
was dependent, at least in part, on TNFa. However, the lack of
TNFa did not completely abrogate chemokine expression,
indicating that there are other factors, induced as a result of
infection, that stimulate chemokine production [39].
In mouse models, gene expression of CXC and CC chemo-
kines has been detected in the lungs after M. tuberculosis
infection [39]. CXCR3-deficient mice [40] have an impaired
granuloma formation after aerosol infection with M. tubercu-
losis, although this effect is transient, occurring at the early
stages of infection. CCR2-deficient mice are extraordinarily
susceptible to moderate- or high-dose M. tuberculosis admin-
istered intravenously [41], and susceptibility is dose-dependent
[42]. Conversely, CCR5 [43] may not be essential to the
development of a protective response to M. tuberculosis infec-
tion. CCL2/MCP-1-deficient mice did not demonstrate an
increased susceptibility to M. tuberculosis infection, but
whether cell infiltration or histology was affected in these mice
was not reported. However, transgenic mice overexpressing
CCL2/MCP-1 were more susceptible to tuberculosis [44].
The CCR5 ligands, CCL3/MIP-1a, CCL4/MIP-1b and
CCL5/RANTES, can attract and activate macrophages and Th1
lymphocytes. However studies in CCR5/ mice have found
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from lymph nodes [43], it is not indispensable for granuloma
formation and immune protection against M. tuberculosis
infection. CCL5/RANTES has been associated with the
generation of type 1 cytokine-producing granulomas [45].
CCR2-deficient mice are extraordinarily susceptible to
moderate- or high-dose M. tuberculosis administered intrave-
nously but not to low aerosol doses [42], and CCL2/MCP-1-
deficient mice do not demonstrate an increased susceptibility to
M. tuberculosis infection [46]. However, there is redundancy in
the chemokine system. Specific to this study, the chemokines
CCL2/MCP-1, CCL3/MIP-1a, CCL4/MIP-1b, and CCL5/
RANTES are ligands of CCR5, but CCL3/MIP-1a and CCL5/
RANTES can also signal through CCR1 and CCR3. This
findings make it difficult to dissect the precise roles of indi-
vidual chemokines and their receptors, suggesting that there are
additional factors that must be induced or enhanced to increase
the ability of the host to eliminate M. tuberculosis infection.
6. Role of D6 and Tir8 receptors in the systemic
inflammation induced by M. tuberculosis infection
Several studies, reporting no signaling function but only
a decoy activity for D6, were mainly addressed to the human
molecule [7], although murine D6 owns the same structural
features and functions as its human orthologue, acting as
a silent receptor and efficient scavenger of inflammatory CC
chemokines [47].
To investigate the role of this receptor in the resolution of
murine inflammatory processes, different inflammation
models were induced in D6-deficient mice (D6/), such as
that locally occurring after subcutaneous injection of
Complete Freund’s adjuvant (CFA) [47], an emulsion of water
in oil composed of inactivated and dried mycobacteria, usually
M. tuberculosis, or after repeated applications of 12-O-tetra-
decanoyl phorbol-13-acetate (TPA), a tumor-promoting agent
mutagenizing skin in murine models of cutaneous malignancy
[48]. The first model of local inflammation was evaluated by
histological analysis of the site of injection at earlier (3 days
after CFA injection) and later (21 days after CFA injection)
time points. At 3 days after CFA injection, D6/ mice were
more susceptible to necrosis, angiogenesis and leukocytes
infiltration when compared to C57BL/6 normal mice, while at
21 days time point, there were no significant differences
between the two groups of mice, both characterized by gran-
uloma-like structures, except for a more intense tissue necrosis
found in D6/ mice.
Moreover, the irritant agent TPA was used to prove the
increased susceptibility of D6/ mice on 2 separate back-
grounds (B6/129 and FVB/N) to develop cutaneous tumors
when compared to normal counterparts [48]. Several appli-
cations of TPA caused an enhanced inflammation of the skin
that was better controlled by normal B6/129 mice than by the
corresponding D6/ mice, showing that D6 limits cytokine
bioavailability in the skin, being crucial for the resolution of
the inflammatory responses that, in some cases, may be
tumorigenic or implicated in carcinoma progression.In addition, studies of inflammatory responses in Tir8-
deficient (Tir8/) mice [15] have reported on an increased
susceptibility to the systemic toxicity of bacterial lipopoly-
saccharide (LPS), and to intestinal inflammation induced
by dextran sulphate sodium (DSS) and colitis-associated
cancer [16].
However, very little is known about a possible negative
regulatory influence of the D6 and Tir8 molecules in tuning
inflammatory responses induced by infection with live
microorganisms. This lack of specific knowledge on the bio-
logical role of decoy receptors in the resolution of infection-
induced inflammatory responses, prompted us to investigate
the role of the D6 and Tir8 receptors in mice infected intra-
nasally with M. tuberculosis [49], known to cause a chronic
inflammatory response.
The expression levels of the D6 receptor, mainly confined
on lymphatic endothelial cells, is not modified in human lungs
and lymph nodes of individuals infected with M. tuberculosis
[49], as well as in lungs, liver and spleen of mice infected with
M. tuberculosis infection [49].
D6/ mice were found highly susceptible to low intranasal
inocula of M. tuberculosis H37Rv (2,000 CFU) with a survival
percentage of about 80% by week 8 and 50% by week 12,
becoming void at week 16. Sinilarly, Tir8/ deficient mice
succumbed to the same M. tuberculosis dose, with a 60% of
mice dying by week 4 and 100% by week 8. In both deficient
strains however, M. tuberculosis CFU loads in the lung, liver
and spleen were not different than in receptor proficient wild-
type mice, clearly indicating that mortality was not due to
failure to control bacterial multiplication and infection.
Histologic analysis revealed severe pulmonary inflamma-
tion with edema and necrotic foci as well as diffuse liver and
kidney necrosis in D6/ mice infected with M. tuberculosis
(see also Fig. 1), while diffuse severe liver damage was the
most important lesion in Tir8/ mice infected with
M. tuberculosis. Supporting these data, M. tuberculosis-
infected receptor-deficient mice had elevated levels of after
serum transaminases and the renal function was severely
compromised with highly increased blood urea nitrogen
(BUN) levels and proteinuria. Thus, although their ability to
control infecting mycobacteria spreading, D6/ and Tir8/
mice have a decreased survival rate associated to lung
inflammation, diffuse liver necrosis and renal tissue damage.
7. D6L/L and Tir8L/L mice display an exaggerated
inflammatory response following M. tuberculosis infection
Lungs and livers of M. tuberculosis-infected D6/ mice
were heavily infiltrated by neutrophils, DCs, macrophages,
NK, gd, CD4þ and CD8þ T cells, when compared to organs of
D6 proficient wild-type mice, at all the time points after
infection. Moreover, CD4þ and CD8þ T cells infiltrating the
lungs of M. tuberculosis infected D6/ mice, at 8 and 12
weeks after infection, showed a higher expression of activation
markers (CD25high, CD44high, CD62Llow),.
Additionally, higher amounts of macrophages, DCs, CD4
and CD8 T lymphocytes had migrated to mediastinal lymph
Fig. 1. Lung sections from wild-type and D6/ mice at 12 weeks after infection withM. tuberculosis. Hematoxylin and eosin stain at 40 magnification. Note that
in D6/ mice the lung space is almost filled with fluid (dark pink staining), infiltrated with predominantly mononuclear cells and few, scattered
polymorphonuclear leukocytes cell, and show evidence of cell necrosis and debris. In wild-type mice much more of the lung airspace is intact, with moderate cell
infiltration.
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nodes caused an increase in the number of specifically primed
T lymphocytes which in turn migrated to lungs, as confirmed
by ELISPOT assays performed on lung leukocytes isolated
from D6/ infected mice stimulated in vitro with irradiated
BCG infected DCs. In fact, at 8 and 12 weeks after
M. tuberculosis infection, the number of IFNg producing
CD4þ and CD8þ T cells was significantly higher in the lungs
of D6/ mice.
As for D6/ mice, the lungs of Tir8/ mice were heavily
infiltrated by immune cells. However, numbers of DCs, NK,
CD4 and CD8 T cells did not differ between Tir8-deficient and
-proficient mice at all tested time points after infection, while
numbers of neutrophils and macrophages were dramatically
increased in Tir8/ mice after 2 and 4 weeks of infection.
The increased recruitment of inflammatory cells in different
organs of receptor-deficient mice may cause massive, local and
systemic production of pro-inflammatory cytokines, such as
TNFa and IL-1b and chemokines, which ultimately cause tissue
damage, as suggested by date reported in the literature [47,49].
Accordingly, lung mononuclear cells from M. tuberculosis-
infected D6/ and Tir8/ mice produced larger amounts of
these cytokines, and, most important and relevant to the
observed phenotype, abundantly higher levels of TNFa and
IL-1b were found in bronchoalveolar lavage and sera of
M. tuberculosis-infected D6- and Tir-8 deficient mice.
Moreover, the lack of D6 receptor also caused an increase
of inflammatory chemokines in blood and inflammed tissues,
as demonstrated by the detection of higher CCL2/MCP-1,
CCL3/MIP-1a, CCL4/MIP-1b and CCL5/RANTES levels in
the bronchoalveolar lavage and serum of D6L/L mice.
To evaluate if the higher levels of circulating pro-inflam-
matory chemokines were indeed responsible M. tuberculosis-
infected D6L/Lmice were treated with a cocktail of antibodies
against the CC chemokines CCL2/MCP-1, CCL3/MIP-1a,
CCL4/MIP-1b and CCL5/RANTES or with antibodies against
each single chemokine, whileM. tuberculosis-infected Tir8L/L
mice were treated with a mixture of blocking antibodies against
TNFa and IL-1b.As expected, the blockade of all the CC chemokines caused
a remarkable reduction of mortality D6/ infected mice, as
showed by only 10% of mice dying by week 12 and 30% of
mice dying by week 16. Also Tir8/ infected mice treated
with neutralizing antibodies to TNFa and IL-1b survived
longer, with a death percentage of only 20% at week 8 and
60% at week 14.
Based on these results, we have hypothesized that D6
and Tir8 deficiency induces an increase of pro-inflammatory
chemokines/cytokines responsible for the massive and
uncontrolled recruitment of immune cells in inflammed sites,
exaggerated inflammatory responses and tissue damage.8. Concluding remarks
Better understanding of the immunological mechanisms of
pathogenesis and protection are of essential importance for the
design of novel vaccines and immunotherapy against tuber-
culosis. It has been proposed, that the protective response to
M. tuberculosis infection, requires CD4 and CD8 lympho-
cytes, the Th1-type cytokines IFN-g and TNF-a, and activated
macrophages. The cooperation between the cells and cyto-
kines requires close interaction, which is achieved following
migration and granuloma formation in the lungs. The hallmark
of infection in the lung is granuloma formation, consisting of
clusters of macrophages, lymphocytes and DCs, which phys-
ically contains the mycobacteria and creates a microenviron-
ment for immune cell interaction, limiting M. tuberculosis
growth and dissemination. However, although the production
of pro-inflammatory cytokines and chemokines is designed to
be protective, if left unchecked, their excessive or inappro-
priate production may lead to severe inflammatory diseases.
Our study indicates an important role for chemokines/cyto-
kines decoy receptors in regulating the extent of the immune
response to M. tuberculosis and suggests that decoy receptors,
through their ability to avoid excessive production of pro-
inflammatory cytokines or to eliminate circulating chemo-
kines, may prevent excessive tissue damage and overall
826 D. Di Liberto et al. / Microbes and Infection 11 (2009) 821e827provide a fine mechanism for the control of the balance
between protective immune responses and immunopathology.
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